Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

INO Stock - Inovio Pharmaceuticals Stock Trading


home / stock / ino

INO INO Quote INO Short INO News INO Articles INO Message Board

MWN AI Summary *

Inovio Pharmaceuticals Inc. (NASDAQ: INO) is a biotechnology company that focuses on developing DNA-based therapies and vaccines for various diseases, with a significant emphasis on oncology and infectious diseases. Founded in 1983 and headquartered in Plymouth Meeting, Pennsylvania, Inovio is renowned for its innovative technology platform, which employs plasmid DNA to elicit immune responses.

One of the notable products in Inovio’s pipeline is INO-4800, a DNA vaccine designed to combat COVID-19. Demonstrating the potential of its platform, INO-4800 went through various stages of clinical trials, aiming to establish its safety and efficacy. The rapid advancement of this vaccine highlighted Inovio’s role in the global fight against the pandemic, showcasing its ability to respond swiftly to urgent health challenges.

Inovio is also actively pursuing treatments for various cancer types through its proprietary immunotherapy approaches. For instance, its lead investigational drug, INO-1400, is aimed at treating patients with certain types of HPV-associated cancers. The company aims to harness the immune system's power to target and kill cancer cells while minimizing damage to healthy tissues.

Despite its potential, Inovio has faced challenges, including regulatory hurdles and increased competition in the biotechnology sector. Its stock has experienced volatility, influenced by clinical trial outcomes and broader market conditions.

As of late 2023, investors remain cautious yet optimistic about Inovio's prospects. The company continues to engage in research collaborations and potential partnerships to bolster its pipeline and accelerate the development of its products. As it navigates the complexities of biotechnology and medicine, Inovio Pharmaceuticals remains a key player to watch in the rapidly evolving life sciences landscape.

MWN AI Analysis *

As of October 2023, Inovio Pharmaceuticals Inc. (NASDAQ: INO) presents an intriguing yet complex investment opportunity. Investors need to consider the company’s recent performance, pipeline developments, and broader market trends before making decisions.

Inovio Pharmaceuticals focuses on the development of DNA-based immunotherapies and vaccines, targeting various diseases, including cancer and infectious diseases. A key factor in Inovio’s market outlook is its progress in clinical trials. As of the latest updates, the company is advancing its lead product candidates, including INO-4800, a COVID-19 vaccine that has garnered attention for its innovative delivery method. However, the competitive landscape for vaccines remains fierce, with many established players dominating the market.

One of the critical current challenges for Inovio is its financial stability. The company has been grappling with ongoing funding requirements to support its research and development efforts. Investors should closely monitor Inovio's funding announcements, including any partnerships or collaborations that could alleviate financial pressure and expedite its clinical programs.

Market sentiment is another crucial component influencing Inovio’s stock performance. The biotechnology sector has experienced heightened volatility driven by regulatory news, clinical results, and macroeconomic factors. Recent trends in the biotechnology sector suggest that stocks may react sharply to any news relating to trial results or FDA approvals. For Inovio, successful trial outcomes mixed with strategic partnerships could bolster investor confidence and lead to potential price appreciation.

In conclusion, while Inovio Pharmaceuticals offers a compelling risk-reward proposition for investors interested in innovative therapies, caution is warranted. Ensure to conduct thorough due diligence, keep pace with clinical developments, and be vigilant regarding the overall financial health of the company. Monitoring industry trends and investor sentiment in the bio-pharmaceutical space will be essential when evaluating potential entry or exit points in the stock.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Inovio Pharmaceuticals Inc. (NASDAQ:INO)

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Quote | Inovio Pharmaceuticals Inc. (NASDAQ:INO)

Last:$1.34
Change Percent: -2.26%
Open:$1.36
Close:$1.34
High:$1.38
Low:$1.32
Volume:2,649,455
Last Trade Date Time:07/08/2025 03:40:15 pm

News | Inovio Pharmaceuticals Inc. (NASDAQ:INO)

  • INOVIO announces pricing of $25M public offering

    2025-07-03 07:57:20 ET More on Inovio Pharmaceuticals Inovio Pharmaceuticals announces proposed public offering of common stock and warrants Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit Seeking Alpha’s Quan...

    • July 03, 2025 07:57:20 am

    • |
    • SeekingAlpha
    • |
      • INO Stock
      • INO Quote
      • INO Short
      • INO News
      • INO Articles
      • INO Message Board
  • INOVIO Announces Pricing of $25 Million Public Offering

    INOVIO Announces Pricing of $25 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and ...

    • July 03, 2025 07:30:00 am

    • |
    • PR Newswire
    • |
      • INO Stock
      • INO Quote
      • INO Short
      • INO News
      • INO Articles
      • INO Message Board

Message Board Posts | Inovio Pharmaceuticals Inc. (NASDAQ:INO)

Subject By Source When
Dengue, zika and chikungunya are among what health KPIFF-LDDFF investorshub 04/29/2023 3:35:53 PM
$INO Ya, you already know the top ten MiamiGent investorshub 04/29/2023 1:53:20 AM
can you put a neoantigen antibody onto the doc2016 investorshub 04/28/2023 6:20:42 PM
Still over 52% institutional ownership Opus X investorshub 04/17/2023 12:38:14 PM
vgxi working on alzheimer vax.....they likely need some ep? doc2016 investorshub 04/09/2023 7:51:58 PM

MWN AI FAQ **

What recent developments or clinical trial results have positively impacted investor sentiment regarding Inovio Pharmaceuticals Inc. (NASDAQ: INO) in the biopharmaceutical sector?

Recent positive developments for Inovio Pharmaceuticals include promising results from their ongoing clinical trials for their DNA-based therapeutics and consistent advancements in their pipeline, which have enhanced investor confidence in the company's potential for innovation and revenue growth.

How does Inovio Pharmaceuticals Inc. (NASDAQ: INO) plan to address challenges related to funding and regulatory approvals for its pipeline products?

Inovio Pharmaceuticals Inc. plans to address funding and regulatory challenges for its pipeline products by pursuing strategic partnerships, enhancing collaboration with stakeholders, and focusing on advancing its innovative DNA medicines through efficient development processes.

Can you provide insights into the competitive landscape for Inovio Pharmaceuticals Inc. (NASDAQ: INO) and how its projects differentiate from those of other biotech firms?

Inovio Pharmaceuticals Inc. (NASDAQ: INO) stands out in the competitive biotech landscape by focusing on its proprietary DNA medicine platform for immunotherapy and vaccine development, aiming to address unmet needs in oncology and infectious diseases, setting it apart from peers.

What are the long-term growth projections for Inovio Pharmaceuticals Inc. (NASDAQ: INO), considering its focus on DNA-based therapeutics and vaccine development?

Long-term growth projections for Inovio Pharmaceuticals Inc. (NASDAQ: INO) are contingent on successful advancements in its DNA-based therapeutics and vaccine development, with potential for increased market share if its clinical trials yield positive results.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get INO Alerts

News, Short Squeeze, Breakout and More Instantly...

Inovio Pharmaceuticals Inc. Company Name:

INO Stock Symbol:

NASDAQ Market:

-2.26% G/L:

$1.34 Last:

2,649,455 Volume:

$1.36 Open:

$1.34 Close:

Inovio Pharmaceuticals Inc. Website:

Inovio Pharmaceuticals Inc. Logo

Ad

Investor Relations
RECENT INO NEWS
  • INO - INOVIO Announces Pricing of $25 Million Public Offering

    INOVIO Announces Pricing of $25 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and ...

  • INO - Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

    LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor ...

  • INO - INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

    INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights PR Newswire On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get INO Alerts

Get INO Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1